- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02531516
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
March 26, 2024 updated by: Aragon Pharmaceuticals, Inc.
ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy results in an improvement of metastasis-free survival.
Study Overview
Status
Active, not recruiting
Conditions
Detailed Description
This is a randomized, double-blind, placebo-controlled, multicenter study of apalutamide plus GnRH agonist compared with GnRH agonist among participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT).
The study will include a Screening Phase, Treatment Phase, a Posttreatment Phase, and a Long-term Follow-up Phase.
Participants will either receive either apalutamide (experimental) or bicalutamide 50 milligram (mg) capsule plus placebo as control group.
Safety will be monitored throughout the study.
Study Type
Interventional
Enrollment (Actual)
1503
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Buenos Aires, Argentina
-
C.a.b.a., Argentina
-
Caba, Argentina
-
Ciudad Autonoma de Buenos Aires, Argentina
-
Pergamino, Argentina
-
Rosario, Argentina
-
San Salvador De Jujuy, Argentina
-
-
-
-
-
Aalst, Belgium
-
Bonheiden, Belgium
-
Brussel, Belgium
-
Haine-St-Paul, Belgium
-
Leuven, Belgium
-
Liège, Belgium
-
Namur, Belgium
-
Roeselare, Belgium
-
Sint-Niklaas, Belgium
-
Turnhout, Belgium
-
Wilrijk, Belgium
-
-
-
-
-
Barretos, Brazil
-
Belo Horizonte, Brazil
-
Campinas, Brazil
-
Curitiba, Brazil
-
Florianopolis, Brazil
-
Goiania, Brazil
-
Ijui, Brazil
-
Natal, Brazil
-
Porto Alegre, Brazil
-
Ribeirao Preto, Brazil
-
Rio de Janeiro, Brazil
-
Salvador, Brazil
-
Santo André, Brazil
-
Sao Jose do Rio Preto, Brazil
-
Sao Paulo, Brazil
-
Sorocaba, Brazil
-
São Paulo, Brazil
-
-
-
-
-
Quebec, Canada
-
-
Alberta
-
Calgary, Alberta, Canada
-
-
British Columbia
-
Surrey, British Columbia, Canada
-
Vancouver, British Columbia, Canada
-
Victoria, British Columbia, Canada
-
-
Ontario
-
London, Ontario, Canada
-
Ottawa, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
Quebec
-
Gatineau, Quebec, Canada
-
Laval, Quebec, Canada
-
Montreal, Quebec, Canada
-
Montréal, Quebec, Canada
-
Sherbrooke, Quebec, Canada
-
-
-
-
-
Beijing, China
-
ChengDu, China
-
ChongQing, China
-
GuangZhou, China
-
Hangzhou, China
-
NanJing, China
-
Nanchang, China
-
Ningbo, China
-
ShangHai, China
-
Wuhan, China
-
Xi'An, China
-
-
-
-
-
Hradec Králove, Czechia
-
Liberec, Czechia
-
Nový Jicin, Czechia
-
Olomouc, Czechia
-
Opava, Czechia
-
Pardubice, Czechia
-
Praha 10, Czechia
-
Praha 2, Czechia
-
Praha 4, Czechia
-
Praha 5, Czechia
-
Praha 8, Czechia
-
Zlin, Czechia
-
-
-
-
-
Amiens, France
-
Angers Cedex 02, France
-
Avignon Cedex 9, France
-
Bayonne, France
-
Besancon, France
-
Bordeaux, France
-
Brest, France
-
Dijon, France
-
Hyères, France
-
La Tronche, France
-
Le Mans, France
-
Lille, France
-
Marseille cedex 05, France
-
Marseilli, France
-
Montpellier, France
-
Neuilly-sur-Seine, France
-
Paris, France
-
Ris Orangis, France
-
Saint Herblain, France
-
Saint-Brieuc, France
-
Saint-Mande, France
-
Saint-Priest-en-Jarez, France
-
Strasbourg, France
-
Toulouse, France
-
Tours, France
-
Vandoeuvre-les-Nancy, France
-
Villejuif Cedex, France
-
Évry-Courcouronnes, France
-
-
-
-
-
Braunschweig, Germany
-
Chemnitz, Germany
-
Dessau, Germany
-
Frankfurt, Germany
-
Gronau, Germany
-
Jena, Germany
-
Münster, Germany
-
Nürtingen, Germany
-
Ulm, Germany
-
Weiden, Germany
-
-
-
-
-
Beer Yaakov, Israel
-
Beer-Sheva, Israel
-
Haifa, Israel
-
Jerusalem, Israel
-
Kfar Saba, Israel
-
Petach-Tikva, Israel
-
Ramat-Gan, Israel
-
Tel-Aviv, Israel
-
-
-
-
-
Daegu, Korea, Republic of
-
Gyeonggi-do, Korea, Republic of
-
Jeollanam-do, Korea, Republic of
-
Seoul, Korea, Republic of
-
-
-
-
-
Georgetown, Malaysia
-
Kuala Lumpur, Malaysia
-
Kuching, Malaysia
-
Putrajaya, Malaysia
-
-
-
-
-
Culiacan, Mexico
-
Guadalajara, Mexico
-
Leon, Mexico
-
Mexico, Mexico
-
Morelia, Mexico
-
Zapopan, Mexico
-
-
-
-
-
Alkmaar, Netherlands
-
Amsterdam, Netherlands
-
Den Haag, Netherlands
-
Nijmegen, Netherlands
-
Rotterdam, Netherlands
-
-
-
-
-
Bialystok, Poland
-
Bydgoszcz, Poland
-
Gdynia, Poland
-
Gliwice, Poland
-
Kielce, Poland
-
Lodz, Poland
-
Olsztyn, Poland
-
Poznan, Poland
-
Walbrzych, Poland
-
-
-
-
-
Bucuresti, Romania
-
Cluj-Napoca, Romania
-
Floresti, Romania
-
Iasi, Romania
-
Otopeni, Romania
-
Ploiesti, Romania
-
Sibiu, Romania
-
Targu Mures, Romania
-
Timisoara, Romania
-
-
-
-
-
Barnaul, Russian Federation
-
Ivanovo, Russian Federation
-
Moscow, Russian Federation
-
Nizhny Novgorod, Russian Federation
-
Obninsk, Russian Federation
-
Omsk, Russian Federation
-
Pyatigorsk, Russian Federation
-
Rostov-on-Don, Russian Federation
-
Ryazan, Russian Federation
-
Saint Petersburg, Russian Federation
-
Saint-Petersburg, Russian Federation
-
Saransk, Russian Federation
-
St Petersburg, Russian Federation
-
Tambov, Russian Federation
-
Tyumen, Russian Federation
-
Ufa, Russian Federation
-
Vologda, Russian Federation
-
-
-
-
-
Barakaldo, Spain
-
Barcelona, Spain
-
Castellon, Spain
-
Hospitalet de Llobregat, Spain
-
Las Palmas de Gran Canaria, Spain
-
Madrid, Spain
-
Málaga, Spain
-
Reus, Spain
-
Santiago de Compostela, Spain
-
Sevilla, Spain
-
-
-
-
-
Stockholm, Sweden
-
Umeå, Sweden
-
Örebro, Sweden
-
-
-
-
-
Kaohsiung, Taiwan
-
Taichung, Taiwan
-
Tainan, Taiwan
-
Taipei, Taiwan
-
Taipei City, Taiwan
-
Taoyuan, Taiwan
-
-
-
-
-
Adana, Turkey
-
Ankara, Turkey
-
Edirne, Turkey
-
Istanbul, Turkey
-
Izmir, Turkey
-
Kayseri, Turkey
-
Kocaeli, Turkey
-
-
-
-
-
Dnipro, Ukraine
-
Khakhiv, Ukraine
-
Kyiv, Ukraine
-
Lviv, Ukraine
-
-
-
-
-
Aberdeen, United Kingdom
-
Birmingham, United Kingdom
-
Bristol, United Kingdom
-
Derby, United Kingdom
-
Glasgow, United Kingdom
-
Oxford, United Kingdom
-
Plymouth, United Kingdom
-
Preston, United Kingdom
-
Sheffield, United Kingdom
-
Sutton, United Kingdom
-
Wolverhampton, United Kingdom
-
-
-
-
Alabama
-
Homewood, Alabama, United States
-
-
Arizona
-
Chandler, Arizona, United States
-
Scottsdale, Arizona, United States
-
Tucson, Arizona, United States
-
-
California
-
Bakersfield, California, United States
-
Los Angeles, California, United States
-
Orange, California, United States
-
San Bernardino, California, United States
-
San Diego, California, United States
-
San Francisco, California, United States
-
-
Colorado
-
Aurora, Colorado, United States
-
Denver, Colorado, United States
-
-
Connecticut
-
Middlebury, Connecticut, United States
-
-
Florida
-
Bradenton, Florida, United States
-
Daytona Beach, Florida, United States
-
Fort Myers, Florida, United States
-
Hialeah, Florida, United States
-
Lakewood Ranch, Florida, United States
-
Naples, Florida, United States
-
Plantation, Florida, United States
-
-
Idaho
-
Meridian, Idaho, United States
-
-
Illinois
-
Evergreen Park, Illinois, United States
-
Harvey, Illinois, United States
-
-
Indiana
-
Jeffersonville, Indiana, United States
-
-
Kansas
-
Wichita, Kansas, United States
-
-
Kentucky
-
Ashland, Kentucky, United States
-
-
Louisiana
-
New Orleans, Louisiana, United States
-
Shreveport, Louisiana, United States
-
-
Maine
-
Scarborough, Maine, United States
-
-
Maryland
-
Baltimore, Maryland, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
-
New Jersey
-
Morristown, New Jersey, United States
-
-
New York
-
Albany, New York, United States
-
Bronx, New York, United States
-
Brooklyn, New York, United States
-
New York, New York, United States
-
Poughkeepsie, New York, United States
-
Rochester, New York, United States
-
Syracuse, New York, United States
-
-
North Carolina
-
Cary, North Carolina, United States
-
Raleigh, North Carolina, United States
-
-
Oregon
-
Portland, Oregon, United States
-
Springfield, Oregon, United States
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, United States
-
Bryn Mawr, Pennsylvania, United States
-
Lancaster, Pennsylvania, United States
-
Philadelphia, Pennsylvania, United States
-
-
Rhode Island
-
East Greenwich, Rhode Island, United States
-
-
South Carolina
-
Charleston, South Carolina, United States
-
Myrtle Beach, South Carolina, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Dallas, Texas, United States
-
Houston, Texas, United States
-
San Antonio, Texas, United States
-
-
Virginia
-
Fairfax, Virginia, United States
-
Virginia Beach, Virginia, United States
-
-
Washington
-
Burien, Washington, United States
-
Spokane, Washington, United States
-
-
West Virginia
-
Morgantown, West Virginia, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age >= 18 years
- Indicated and planned to receive primary radiation therapy for prostate cancer
- Histologically confirmed adenocarcinoma of an intact prostate, and 1 of the following at diagnosis: 1) Gleason score >=8 and >=cT2c, 2) Gleason score >=7, PSA >=20 nanogram per milliliters (ng/mL), and >=cT2c
- Charlson index (CCI) <=3
- An Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) grade of 0 or 1
- Adequate organ function: (1) aspartate aminotransferase (AST), alanine aminotransferase (ALT), within normal limits (WNL), (2) serum creatinine less than (<) 1.5 milligram/deciliter (mg/dL) (<133 micromoles/Liter [mcmol/L]), (3) platelets greater than or equal to (>=)140,000/microLiter (mcL), independent of transfusion and/or growth factors within 3 months prior to randomization, (4) Hemoglobin >= 12.0 gram/deciliter (g/dL) (7.4 millimloes [mmol], independent of transfusion and/or growth factors within 3 months prior to randomization
- Participants who are sexually active (even men with vasectomies) and willing to use a condom and agree not to donate sperm during the trial
- Signed, written, informed consent
- Be able to swallow whole study drug tablets
Exclusion Criteria: -
- Presence of distant metastasis, (clinical stage M1). Isolated pelvic nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion. Diagnosis of distant metastasis (clinical M stage; M0 versus M1a, M1b, M1c) and pelvic nodal disease (clinical N stage; N1 versus N0) will be assessed by central radiological review. Patients are considered eligible only if the central radiological review confirms clinical stage M0.
- Prior treatment with gonadotropin releasing hormone (GnRH) analogue or anti-androgen or both for >3 months prior to randomization
- Bilateral orchiectomy
- History of pelvic radiation
- Prior systemic (example [e.g.], chemotherapy) or local (e.g. radical prostatectomy, cryotherapy) treatment for prostate cancer
- History of seizure or any condition that may predispose to seizure (including, but not limited to prior stroke, transient ischemic attack or loss of consciousness <= 1 year prior to randomization; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
- Prior treatment with enzalutamide, abiraterone acetate, orteronel, galeterone, ketoconazole, aminoglutethimide, estrogens, megestrol acetate, and progestational agents (including cyproterone acetate) for prostate cancer
- Prior treatment with radiopharmaceutical agents (e.g., strontium-89) or immunotherapy (e.g., sipuleucel-T) for prostate cancer
- Prior treatment with systemic glucocorticoids ≤4 weeks prior to randomization or is expected to require long-term use of corticosteroids during the study
- Use of 5-alpha reductase inhibitors (e.g., dutasteride, finasteride) <=4 weeks prior to randomization
- Use of any investigational agent <=4 weeks prior to randomization
- Current chronic use of opioid analgesics for >=3 weeks for oral or >7 days for non-oral formulations
- Major surgery <=4 weeks prior to randomization
- Current or prior treatment with anti-epileptic medications for the treatment of seizures
- Gastrointestinal conditions affecting absorption
- Known or suspected contraindications or hypersensitivity to apalutamide, bicalutamide or GnRH agonists or any of the components of the formulations
- Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Apalutamide
Participants will receive apalutamide (240 mg), by mouth, once daily for overall 30 months, plus bicalutamide placebo, by mouth, once daily, for four months from randomization.
All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
|
|
Active Comparator: Control group
Participants will receive apalutamide placebo, by mouth, once daily for overall 30 months, plus bicalutamide (50 mg), by mouth, once daily, for four months from randomization.
All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metastasis-free survival
Time Frame: 108 Months
|
Metastasis-free survival is defined as the time from randomization to the date of the first occurrence of radiographic bone or soft tissue distant metastasis based on conventional imaging by blinded independent central review (BICR), histopathologic diagnosis of distant metastasis, or death from any cause, whichever occurs first.
|
108 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event-free Survival
Time Frame: 108 Months
|
Event-free survival is defined as the time from randomization to the date of the first occurrence of prostate specific antigen (PSA) failure by the Phoenix definition, local or regional disease recurrence on conventional imaging by BICR or histopathologic diagnosis, distant metastasis on conventional imaging by BICR or histopathologic diagnosis, or death.
|
108 Months
|
Time to Prostate Specific Antigen (PSA) Progression
Time Frame: 108 Months
|
Time to PSA progression is defined as time from randomization to the date of PSA nadir plus (+) 0.5 nanograms per milliliter (ng/mL) and rising.
|
108 Months
|
Overall Survival (OS)
Time Frame: 108 Months
|
OS is defined as the time from randomization to date of death from any cause.
|
108 Months
|
Time to Distant Metastasis
Time Frame: 108 Months
|
Time to distant metastasis is defined as the time from randomization to the date of the first occurrence of radiographic or pathological bone or soft tissue distant metastasis on conventional imaging by BICR or histopathologic diagnosis of distant metastasis.
|
108 Months
|
Time to Next Local or Systemic Treatment
Time Frame: 108 Months
|
Time to next local or systemic treatment defined as time from randomization to first subsequent therapy, including re-initiation of androgen deprivation therapy (ADT) and local treatments for local-regional recurrence or distant metastasis.
|
108 Months
|
MFS by Conventional or Positron Emission Tomography (PET) Imaging
Time Frame: 108 Months
|
MFS by conventional or PET imaging is defined as time from randomization to the date of the first occurrence of radiographic bone or soft tissue distant metastasis based on conventional imaging or PET imaging, histopathologic diagnosis of distant metastasis, or death from any cause, whichever occurs first.
|
108 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Aragon Pharmaceuticals, Inc. Clinical Trial, Aragon Pharmaceuticals, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 19, 2015
Primary Completion (Estimated)
June 28, 2024
Study Completion (Estimated)
December 29, 2028
Study Registration Dates
First Submitted
August 21, 2015
First Submitted That Met QC Criteria
August 21, 2015
First Posted (Estimated)
August 24, 2015
Study Record Updates
Last Update Posted (Actual)
March 27, 2024
Last Update Submitted That Met QC Criteria
March 26, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Androgen Antagonists
- Bicalutamide
Other Study ID Numbers
- CR106935
- 56021927PCR3003 (Other Identifier: Aragon Pharmaceuticals, Inc.)
- 2015-003007-38 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
Clinical Trials on Bicalutamide
-
University of Wisconsin, MadisonPfizerTerminatedProstate CancerUnited States
-
Fox Chase Cancer CenterCompletedCancer of ProstateUnited States
-
University of L'AquilaCompletedProstate CancerItaly
-
AstraZenecaNo longer availableAdenocarcinoma of the Prostate
-
Alessa Therapeutics Inc.CompletedLower Urinary Tract Symptoms | Prostate AdenocarcinomaUnited States, Australia, New Zealand
-
Royal College of Surgeons, IrelandUniversity College Dublin; University of Oxford; University of Liverpool; University...Not yet recruitingPolycystic Ovary Syndrome | Metabolic Disease | Androgen ExcessIreland
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)Withdrawn
-
SandozCompleted
-
SandozCompleted
-
Astellas Pharma IncMedivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedProstatic NeoplasmsUnited States, Belgium, Canada, Denmark, France, Germany, Romania, United Kingdom